科研之友
微信
新浪微博
Facebook
分享链接
摘要
<jats:sec><jats:label /><jats:p>Melatonin, <jats:italic>N</jats:italic>‐acetyl‐5‐methoxytryptamine, an evolutionally old molecule, is produced by the pineal gland in vertebrates, and it binds with high affinity to melatonin receptors, which are members of the GPCR family. Among the multiple effects attributed to melatonin, we will focus here on those that are dependent on the activation of the two mammalian MT<jats:sub>1</jats:sub> and MT<jats:sub>2</jats:sub> melatonin receptors. We briefly summarize the latest developments on synthetic melatonin receptor ligands, including multi‐target‐directed ligands, and the characterization of signalling‐biased ligands. We discuss signalling pathways activated by melatonin receptors that appear to be highly cell‐ and tissue‐dependent, emphasizing the impact of system bias on the functional outcome. Different proteins have been demonstrated to interact with melatonin receptors, and thus, we postulate that part of this system bias has its molecular basis in differences of the expression of receptor‐associated proteins including heterodimerization partners. Finally, bias at the level of the receptor, by the expression of genetic receptor variants, will be discussed to show how a modified receptor function can have an effect on the risk for common diseases like type 2 diabetes in humans.</jats:p></jats:sec><jats:sec><jats:title>Linked Articles</jats:title><jats:p>This article is part of a themed section on Recent Developments in Research of Melatonin and its Potential Therapeutic Applications. To view the other articles in this section visit <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc">http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc</jats:ext-link></jats:p></jats:sec>
- 出版日期2018-8
- 单位常州工学院
